Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03750981 · ClinicalTrials.gov registry record · NA

C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)

A NA study of Cancer Survivors, sponsored by Barbara Ann Karmanos Cancer Institute.

Recruiting
Registry status
NA
Development phase
500
Enrollment target
1
Study location

NCT03750981 is a NA study of Cancer Survivors that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 500 participants, above the 72-participant average among 11 other Cancer Survivors trials with a reported enrollment target (594% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03750981, a NA study of Cancer Survivors, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.

RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.

Conditions Studied

Interventions

  • BEHAVIORAL 12 week pilot intervention study.

Study Locations (1)

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2018-11-12
Est. Completion 2028-11-30
Phase NA

What the Registry Record Tells You About NCT03750981

The ClinicalTrials.gov registry entry for NCT03750981 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 11 other Cancer Survivors trials with a reported enrollment target (594% higher). The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer Survivors appearing as the primary indexed condition, and to 1 intervention - of which 12 week pilot intervention study. is the first listed.

NCT03750981 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT03750981 about?

NCT03750981 is a clinical study titled "C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)". This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer su...

What is the current status of trial NCT03750981?

This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2018-11-12. Estimated completion is 2028-11-30.

What conditions does trial NCT03750981 study?

This clinical trial studies the following conditions: Cancer Survivors.

What interventions are being tested in trial NCT03750981?

The interventions under investigation include: 12 week pilot intervention study. (BEHAVIORAL).

Who is sponsoring clinical trial NCT03750981?

This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03750981 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Survivors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.